Global Glioblastoma Multiforme (GBM) Industry Landscape, 2030 - Featuring Genentech, Merck, VBL Therapeutics, Diffusion Pharma, Bayer, and More
December 24, 2021 07:13 ET
|
Research and Markets
Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme (GBM) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. ...
Global Glioblastoma Multiforme Treatment Markets Analysis & Forecasts, 2017-2020 & 2021-2028
December 01, 2021 05:13 ET
|
Research and Markets
Dublin, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By...
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
November 22, 2021 09:25 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their...